日本过敏性鼻炎临床实践指南作者的财务与学术利益冲突
该横断面分析基于日本79家药企2016–2017年支付数据,评估2版过敏性鼻炎指南共27名作者的财务与学术利益冲突。96.3%作者至少获1笔支付,两年合计1333552美元,人均均值49391美元、中位18400美元;指南作者自引率2016年47.6%、2020年27.9%,两版均无正式利益冲突声明。
要点
- 27名指南作者中26人(96.3%)接受药企支付,两年合计1333552美元。
- 人均支付均值49391美元、中位18400美元,新药企业为主要支付方。
- 指南作者自引率2016年47.6%、2020年27.9%,两版均无正式利益冲突声明。
核心结论
- 过敏性鼻炎指南作者与药企存在显著财务关系,尤其新药企业。
- 指南作者自引率较高,提示潜在学术利益冲突。
- 需更严格全面的利益冲突管理策略。
研究设计与样本
- 横断面分析日本79家药企2016–2017年支付数据。
- 纳入2版主要过敏性鼻炎指南共27名作者。
- 通过计算指南相关研究自引评估学术利益冲突。
主要发现
- 27名作者中26人(96.3%)至少获1笔支付,两年合计1333552美元。
- 人均支付均值49391美元(SD 67438),中位18400美元(IQR 6216–72494)。
- 新药企业为主要支付方。
- 指南作者自引占比2016年47.6%、2020年27.9%。
- 两版指南均无正式利益冲突声明。
临床怎么用
- 解读过敏性鼻炎指南推荐时需考虑作者财务与学术利益冲突。
- 指南制定应建立正式利益冲突披露与管理机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate financial and intellectual conflicts of interest (COIs) among clinical practice guideline (CPG) authors of allergic rhinitis in Japan and to evaluate the extent of transparency and accuracy in COIs by CPG authors of allergic rhinitis. STUDY DESIGN: A cross-sectional analysis of the payment data from all 79 pharmaceutical companies in Japan between 2016 and 2017. SETTING: Japan. METHODS: We considered all 27 CPG authors from 2 different versions of the most prominent CPGs for allergic rhinitis in Japan. Using payment data disclosed by 79 major pharmaceutical companies between 2016 and 2017, we assessed the magnitude and characteristics of financial COIs of CPG authors. We also evaluated the intellectual COIs of the CPG authors by counting self-citations of research articles related to CPG statements and recommendations. RESULTS: Of 27 CPG authors, 26 authors (96.3%) received at least 1 payment from a combined total of $1,333,552 between 2016 and 2017. The 2-year combined average and median monetary values per author were $49,391 (SD, $67,438) and $18,400 (interquartile range: $6,216-$72,494), respectively. Pharmaceutical companies with novel drugs predominantly made these payments. The percentage of citations with at least 1 CPG author relative to total citations was 47.6% in 2016 and 27.9% in 2020. There were no formal COI disclosure statements in either version. CONCLUSION: This study found that allergic rhinitis CPG authors had significant financial relationships with pharmaceutical companies, particularly those marketing novel drugs. In addition, CPG authors had relatively high self-citation rates, a potential marker of intellectual COIs. More rigorous and comprehensive COI management strategies are needed.
引用
- Murayama A, Kida F, Ozaki A, et al. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg. 2021. PMID: 34399654. doi:10.1177/01945998211034724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。